What are Mission Vision & Core Values of Myriad Company?

How does Myriad Genetics guide precision medicine with its mission and vision?

The company’s strategic statements direct long-term value creation and clinical impact, aligning stakeholders around genomic-driven care. Myriad leverages diagnostics to translate data into actionable treatment decisions across oncology and mental health.

Mission, vision and values act as Myriad’s compass, steering investment toward oncology and pharmacogenomics while emphasizing scientific integrity and patient outcomes. See strategic context in Myriad Porter's Five Forces Analysis.

Myriad Company mission statement centers on delivering actionable genetic insights to patients and clinicians, expanding access to precision care across oncology and mental health while prioritizing patient outcomes and clinical utility.

Dual customer focus

Targets individual patients and healthcare providers to support collaborative care decisions.

Precision medicine

Uses genetic testing to reduce trial-and-error treatments, notably in psychotropic prescribing.

Market expansion

Universal germline testing for all cancer patients broadens reach and equity in care.

Evidence-driven

Clinical utility emphasized through outcomes and adoption metrics in 2025.

Proven reach

By 2025 the GeneSight test has guided medication choice for over 2.5 million patients, demonstrating scale.

Customer-centric value

Focuses on utility of results for end-users rather than sequencing alone.

Myriad Company purpose and guiding principles emphasize scalable genetic solutions that improve outcomes, supported by evidence such as GeneSight's > 2.5 million patient uses and the 2025 rollout of universal germline testing for cancer care. Read more in Competitors Landscape of Myriad

Complete Myriad Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

To be the most trusted advisor for patients and healthcare providers, guiding lifelong genomic decisions across prevention, diagnosis and treatment with trusted data, clinical support and global reach.

Trusted lifelong partnership

Shifts focus from episodic testing to ongoing genomic guidance across life stages.

Leadership in MRD and liquid biopsy

2025 investments prioritize MRD monitoring and liquid biopsy to enable early intervention.

Data-driven clinical support

Moving into data management and decision support to add clinical value beyond single tests.

Global ambition

Aims to serve patients at prenatal, oncology and geriatric milestones worldwide.

Trust as currency

Prioritizes privacy, accuracy and clinician partnerships to build sustained trust.

Platform evolution

Transitioning from a single-test lab to an integrated diagnostic platform and longitudinal genomics leader.

To be the most trusted advisor for patients and healthcare providers as they navigate genetic testing across life, combining MRD, liquid biopsy and longitudinal genomics into actionable care.

Growth Strategy of Myriad

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Core values guide behavior and decisions at Myriad Company, shaping culture and market actions. These principles drive patient-centered care, scientific excellence, innovation, and ethical accountability across operations.

Patients First

Clinical utility and patient advocacy take precedence over commercial gain, supported by programs that enabled access to testing for over 80,000 patients in the last fiscal year.

Scientific Rigor

Decisions are evidence-based, backed by more than 1,000 peer-reviewed studies and validation of AI-driven risk models against clinical outcomes before deployment.

Innovation

R&D investment of roughly 10–12% of revenue fuels advances such as NGS adoption and the FirstGene prenatal screen to simplify testing workflows.

Integrity and Accountability

Strict data privacy protocols and transparent clinical reporting establish trust with health systems and biopharma partners for trials and population health initiatives.

Explore how the Myriad Company mission statement and vision translate into strategic decisions and operational priorities in the next chapter; read the company background here: Brief History of Myriad

Myriad Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Mission and vision shape strategic decisions by setting long-term priorities and aligning capital allocation with stated purpose; they guide product focus, partnerships, and operational metrics. Clear mission and vision reduce strategic drift and enable measurable portfolio shifts toward higher-growth areas.

Myriad Company mission, vision & core values

The mission directs resource allocation to precision health while the vision frames long-term patient engagement and platform development.

• The mission emphasizes empowering providers and patients with actionable genetic insights
• The vision positions the company as a lifelong advisor through digital health and patient portals
• Core values prioritize scientific rigor, patient-centricity, integrity, and collaboration
• Strategic metrics tie mission to outcomes: revenue mix, turnaround time, and growth in target segments

Strategic pivot to high-growth focus

In 2025 the company shifted capital away from non-core assets to focus on Precise Oncology and Mental Health.

Measured outcomes

15 percent year-over-year growth in the oncology portfolio as of Q2 2025 illustrates mission-driven results.

Operational improvements

Average turnaround time for MyRisk reduced to under 7 days, aligning operational KPIs with the mission to empower providers.

Leadership alignment

CEO and leadership cite the 'lifelong advisor' vision when prioritizing digital health tools and patient engagement platforms.

Market expansion rationale

Partnerships with integrated delivery networks were chosen to normalize genetic insights as part of standard care, consistent with company purpose.

Where to find values and governance

Official values and governance details appear in investor materials and corporate responsibility reports, which inform hiring, compliance, and product roadmaps.

The mission and vision drove divestitures and reallocation to Precise Oncology and Mental Health, producing 15% oncology growth and faster MyRisk turnaround; read the next chapter on Core Improvements to Company's Mission and Vision and see how these shifts translate to product and cultural changes: Revenue Streams & Business Model of Myriad

Influence: Mission and vision prompted the 2025 high-growth, high-margin pivot; divestment of the autoimmune business funded focus on Precise Oncology and Mental Health, producing 15 percent YoY oncology growth (Q2 2025). Leadership: CEO cites the 'lifelong advisor' vision to expand digital health and portals. Market expansion: IDN partnerships driven by the mission to make genetic insights standard of care. Operations: MyRisk turnaround reduced to under 7 days, reflecting mission-led efficiency.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE

Four targeted improvements can tighten Myriad Company mission and vision to reflect technological leadership and social responsibility. These refinements aim to clarify strategic direction for investors, partners, and patients.

Explicitly declare AI-enabled genomics

Update the Myriad Company mission statement to state leveraging advanced computational biology and AI to translate genomic data into actionable clinical insights, aligning with industry trends where AI-driven diagnostics grew by over 35% CAGR from 2019–2024.

Position as a technology-first insights company

Shift language from purely laboratory-focused to 'technology-driven insights' to signal to investors that Myriad Company purpose includes building scalable digital platforms—digital health market value projected to exceed $600B by 2025.

Embed explicit ESG and equitable access commitments

Refine the Myriad Company vision to commit to reducing genomic health disparities with measurable targets (for example, improving underserved testing access by 25% within five years) to meet investor ESG expectations rising in 2025.

Publish measurable guiding principles and KPIs

Adopt clear Myriad Company core values tied to KPIs—data privacy, accuracy, access, and innovation—with regular public reporting to improve stakeholder trust and compare favorably to peers like Exact Sciences.

Improvements

While Myriad’s mission and vision are robust, they could be strengthened by more explicitly addressing the role of artificial intelligence and digital transformation; industry best practices increasingly position 'data-driven' or 'AI-enabled' insights as core identity elements. Myriad could refine its mission to include 'leveraging advanced computational biology to unlock the full potential of the human genome,' signaling to investors that Myriad Company is evolving from a laboratory company into a technology-driven insights company; additionally, updating the vision to commit to equitable access and measurable reductions in genomic health disparities aligns with 2025 ESG trends and consumer expectations—compare to Exact Sciences' broad early-detection positioning for 'everyone' to see the strategic benefit of a stronger equity-focused stance.

For further context, see Owners & Shareholders of Myriad